STIFEL 2026 HEALTHCARE CONFERENCE - 4D MOLECULAR THERAPEUTICS INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures disclosed; the company confirms a strong cash position with a runway extending into the second half of 2028.
• Financial strategy anticipates reimbursement via the standard "buy and bill" model, which aligns with current retina clinic economics.
• Management projects that despite potential volume reduction from treatment burden cuts, the higher upfront price point of the gene therapy and the capture of "value loss" from patients dropping off current therapies (up to 60% at 5 years) will create a favorable economic model.

Guidance and Future Outlook:

• 2027 Timeline: Top-line results scheduled for the Forefront 1 trial (Q2 2027) and Forefront 2 trial (H2 2027).
• Regulatory Status: The company holds RMAT designation from the FDA and Prime designation from the EMA, with productive interactions noted with the PMDA for global approval.
• Growth Outlook: Aims to establish 4D-150 as a "backbone therapy" capable of lifelong continuous disease control, potentially reducing the current episodic treatment burden by 80-90% and rendering a significant portion of patients injection-free.

Business Segments and Product Lines:

• Lead Asset (4D-150): An intravitreal gene therapy using the proprietary R100 capsid vector to deliver aflibercept (VEGF Trap) transgenes to the retina.
• Mechanism: Designed as a single-dose "backbone therapy" to provide continuous, 24/7 disease control for wet Age-Related Macular Degeneration (wAMD), contrasting with current episodic bolus injections.
• Development Status: Phase 3 trials (Forefront 1 and 2) are fully enrolled; Phase 2 (PRISM) data showed 87% treatment burden reduction vs. standard of care and 66% of patients being injection-free at 2 years.
• Clinical Design: Trials focus on treatment-naive or recently diagnosed patients to align with FDA requirements for vision benefit; includes a 20-week prophylactic steroid regimen (Durazol) to manage inflammation.

Market and Competitive Landscape:

• Market Size: The wAMD sector is a $16 billion market driven by an aging population and continuous innovation.
• Differentiation:
  • vs. Standard of Care: Shifts from episodic, finite treatment to a continuous, lifelong control paradigm.
  • vs. Competitors:
    • Regenexx: Delivers gene therapy via subretinal surgery (requires OR), whereas 4D-150 is intravitreal (clinic-based).
    • Adverum/Lilly: Uses a high-dose, intravitreal approach; 4DMT argues their R100 vector allows for lower doses with higher tissue specificity, potentially mitigating safety risks associated with high-dose inflammatory events seen in Adverum's history.
• Adoption Strategy: Targets alignment with physicians by addressing clinic capacity constraints (40% of docs report full capacity) and offering a more efficient workflow than frequent bolus injections.

Risks and Challenges:

• Safety: Gene therapies carry inherent risks of inflammation, occlusive retinal vasculitis, endophthalmitis, or retinal detachment; however, management reports no serious adverse events or inflammation in the 71 patients treated at Phase 3 doses (post-steroid regimen).
• Reimbursement & Economics: Uncertainty remains regarding the final pricing strategy; the economic model relies on the "buy and bill" capitation not being eroded by the reduced frequency of administration.
• Trial Variability: Management designed strict retreatment criteria (e.g., 5-letter vision loss or specific anatomical shifts) to reduce data variability, but real-world adherence to these criteria could impact trial readouts.
• Market Competition: Multiple other gene therapy programs and extended-duration biologics are in development, potentially diluting the market if 4D-150 does not demonstrate clear superior efficacy.

Management Commentary and Tone:

• Tone: Highly confident and optimistic; management describes the potential impact of 4D-150 as "paradigm-shifting" and "best-in-class."
• Key Messages: Emphasizes the biological mismatch of current treatments (episodic vs. chronic disease) and positions 4D-150 as the necessary "continuous control" solution.
• Physician Sentiment: Reports overwhelming enthusiasm from retina physicians regarding the reduction of treatment burden and the potential to free up clinic capacity.
• Patient Appeal: Highlights that patient anxiety regarding the current treatment regimen is high, and the prospect of a single dose is viewed very positively by patients.

Analyst Questions and Answers:

• Trial Design Success: Management attributes high probability of success to studying treatment-naive patients (aligning with FDA guidance) and strict anatomical/criteria-based retreatment rules that prioritize vision preservation.
• Retreatment Expectations: While hesitant to give a binary number, management expects retreatment reduction rates in the 80-90% range for recently diagnosed patients, with 40-60% treatment-free rates.
• Safety Protocols: Confirmed that the 20-week steroid regimen has been well-received by patients, with no physician hesitation reported; the safety profile is attributed to the tissue-specific R100 vector and low dosing.
• Competitive Landscape: Acknowledges the busy market but asserts that 4D-150's intravitreal delivery (clinic vs. OR) and low-dose approach differentiate it significantly from subretinal (Regenexx) and high-dose (Adverum) competitors.
• Clinic Economics: Addressed concerns about doctors losing revenue from fewer injections by explaining the higher upfront price point of the gene therapy and the capture of value from patients who currently drop off standard care.

Other Key Points:

• PRISM Data: Phase 2 data for recently diagnosed patients showed sustained central subfield thickness control and visual acuity maintenance over two years.
• Commercial Readiness: The product is designed to fit seamlessly into existing retina clinic workflows as a single intravitreal injection, requiring no specialized surgical infrastructure.
• Long-term Vision: The goal is not just incremental durability gains (e.g., +10 days) but a fundamental shift to a "lifetime injection-free" standard for wAMD.
• Regulatory Interactions: Strong support from global regulators (FDA, EMA, PMDA) has been maintained, with the trials designed to support global approval.